Biomarkers of Whole Grain Wheat and Rye Intake

Sponsor
King's College London (Other)
Overall Status
Completed
CT.gov ID
NCT02155062
Collaborator
(none)
10
1
3
4
2.5

Study Details

Study Description

Brief Summary

Alkylresorcinols (AR) are a group of lipids found in the bran fraction of wheat and rye grains. AR are absorbed into the bloodstream and their metabolites are excreted in urine in measurable amounts following ingestion of wholegrain (WG) wheat or rye cereal. As AR are absent in refined cereals, plasma AR and urinary AR metabolites are proposed as suitable biomarkers of dietary intake of WG wheat and rye cereal, with a number of studies supporting this proposal. Different AR species are present in characteristic quantities in WG wheat in comparison to WG rye cereals, which can allow identification of the main source of WG (wheat or rye) in individuals by analysing the AR concentrations in blood. However the patterns of urinary AR metabolite excretion following wheat or rye intake have not yet been investigated to determine if there are differences according to WG source.

The present study aims to:

(i) investigate the differences in AR metabolite excretion pattern in spot and 24 hour urine samples after following a predominantly WG rye-based diet in comparison to a predominantly WG wheat-based diet and in comparison to control (refined cereal diet) (ii) compare the validity and reproducibility of AR metabolites in spot urine samples in comparison to 24 hour urine samples.

Condition or Disease Intervention/Treatment Phase
  • Other: Whole grain rye
  • Other: Whole grain wheat
  • Other: Refined cereal
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Urinary Alkylresorcinol Metabolites as a Biomarker of Whole Grain Wheat and Rye Intake
Study Start Date :
May 1, 2014
Actual Primary Completion Date :
Sep 1, 2014
Actual Study Completion Date :
Sep 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Whole grain rye

3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)

Other: Whole grain rye

Other: Refined cereal

Experimental: Whole grain wheat

3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)

Other: Whole grain wheat

Other: Refined cereal

Placebo Comparator: Refined cereal

No intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)

Other: Refined cereal

Outcome Measures

Primary Outcome Measures

  1. 24-h urinary DHBA:DHPPA ratio [Endpoint (Day 3)]

    DHBA: 3,5-dihydroxybenzoic acid DHPPA: 3-(3,5-dihydroxyphenyl)-propanoic acid DHBA & DHPPA are the main AR metabolites excreted in urine

Secondary Outcome Measures

  1. DHBA:DHPPA ratio in morning spot urine [Endpoint (Day 3)]

  2. Total 24-h urinary AR metabolite (DHBA + DHPPA) excretion [Endpoint (Day 3)]

  3. Total 24-h urinary DHBA excretion [Endpoint (Day 3)]

  4. Total 24-h urinary DHPPA excretion [Endpoint (Day 3)]

  5. 24-h urinary total AR (DHBA+DHPPA):creatinine ratio [Endpoint (Day 3)]

  6. 24-h urinary DHBA:creatinine ratio [Endpoint (Day 3)]

  7. 24-h urinary DHPPA:creatinine ratio [Endpoint (Day 3)]

  8. Total AR (DHBA+DHPPA):creatinine ratio in morning spot urine sample [Endpoint (Day 3)]

  9. DHBA:creatinine ratio in morning spot urine sample [Endpoint (Day 3)]

  10. DHPPA:creatinine ratio in morning spot urine sample [Endpoint (Day 3)]

Other Outcome Measures

  1. Estimated daily intake of WG wheat and rye cereals [Assessed throughout each intervention period (Days 1-3)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Body mass intake 18.5-30.0 kg/m2

  • Weight stable for 2 months

  • Generally healthy

Exclusion Criteria:
  • Previous or current chronic disease including heart disease, diabetes, gastrointestinal, liver, renal or endocrine disorders

  • Drug or alcohol misuse in the last year

  • Current pregnancy or lactation

  • Weight change of >3 kg in the last two months

  • Current regular user of certain prescription medications (except contraceptives)

  • Unwilling to consume or to stop consuming WG wheat, WG rye or refined cereals

  • Unwilling to discontinue multivitamins/dietary supplements during study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Diabetes and Nutritional Sciences Division, King's College London London United Kingdom SW1 9NH

Sponsors and Collaborators

  • King's College London

Investigators

  • Principal Investigator: Julia Darzi, PhD, King's College London

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Julia Darzi, Lecturer Nutrition and Dietetics, King's College London
ClinicalTrials.gov Identifier:
NCT02155062
Other Study ID Numbers:
  • BDM/13/14-78
First Posted:
Jun 4, 2014
Last Update Posted:
Mar 6, 2015
Last Verified:
Mar 1, 2015
Keywords provided by Dr Julia Darzi, Lecturer Nutrition and Dietetics, King's College London

Study Results

No Results Posted as of Mar 6, 2015